Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06328738 2025-11-19

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Phase 1 Active not recruiting

275 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03716180 2025-09-22

DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC

Phase 1 Active not recruiting

100 enrolled

Breast

Breast Neoplasms

NCT05385705 2025-09-22

A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020

Phase 1 Terminated

2 enrolled

Breast

Breast Neoplasms

NCT06239467 2025-09-09

PIKture-01

Phase 1 Recruiting

200 enrolled

Breast

Breast Neoplasms

NCT04487236 2025-08-11

Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors

Phase 1 Completed

61 enrolled

CNS

Brain Neoplasms

NCT06886659 2025-07-22

A Study to Compare PK, Immunogenicity and Safety of Trastuzumab of Incepta Pharmaceuticals Ltd With Trastuzumab (Roche)

Phase 1 Completed

80 enrolled

Breast

Breast Diseases, Breast Neoplasms

NCT03767335 2025-06-26

B-PRECISE-01

Phase 1 Completed

62 enrolled 18 charts

Breast

Breast Neoplasms

NCT00393783 2025-06-05

Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity

Phase 1 Active not recruiting

13 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04188548 2025-06-04

EMBER

Phase 1 Active not recruiting

500 enrolled

BreastGynecologic

Breast Neoplasms, Endometrial Neoplasms

NCT03432741 2025-05-26

Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Phase 1 Terminated

17 enrolled

BreastDermatologicLymphoid

Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT01649271 2025-02-11

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Phase 1 Completed

13 enrolled 11 charts

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT00950742 2025-02-10

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

Phase 1 Completed

18 enrolled 14 charts

Breast

Breast Neoplasms

NCT02705859 2025-01-09

Panther

Phase 1 Completed

26 enrolled

Breast

HER2 Positive Breast Cancer

NCT01921335 2024-11-06

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Phase 1 Completed

41 enrolled

Breast

Breast Neoplasms

NCT04120246 2024-07-10

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Phase 1 Suspended

24 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00963547 2024-06-04

MK-2206-015

Phase 1 Terminated

33 enrolled 13 charts

Breast

Breast Neoplasms

NCT05143970 2024-03-20

CHANCES

Phase 1 Unknown

27 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06162559 2024-01-11